Omeros corporation receives decision from fda on formal dispute resolution request for narsoplimab

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the office of new drugs (ond) of the u.s. food and drug administration (fda) has reached a decision on the company's formal dispute resolution request appealing the issuance by fda's office of cardiology, hematology, endocrinology and nephrology (ochen) and the division of nonmalignant hematology (the review division) of a complete response letter (crl) concerning the biologics license application (bla) for narsopl
OMER Ratings Summary
OMER Quant Ranking